Adult GlioblastomaPhase 1NCT04573140Papers
Autologous total tumor mRNA
RNA-lipid Particle (RNA-LP) Vaccines for Newly Diagnosed Pediatric High-Grade Gliomas (pHGG) and Adult Glioblastoma (GBM)
An AAV Mediated Dual-Payload Gene Therapy in Patients With High Grade Glioma
What the film says
Glioblastoma is the most common cancer that starts in the adult brain. About eleven thousand people in the United States hear that diagnosis each year, most of them in their sixties. The standard plan is surgery, then radiation with a chemotherapy pill. It helps, but rarely finishes the job. In the trial that set today's standard, half of patients lived under fifteen months.
The reason is the shape of the thing. A glioblastoma has no edge. Its cells wander off into healthy brain, so surgery cannot reach them all. And a few of those cells behave like stem cells. Given time, they rebuild the whole tumor.
So imagine a gene that could kill those cells. Could you put it into a brain safely?
That is the real problem. Delivery is not the hard part; address is. Anything strong enough to kill a tumor cell will damage a neuron if it switches on in the wrong place. Gene therapies handle this with a promoter, a piece of DNA that works as an on switch for a nearby gene. But the switches available are either too weak or too leaky.
So a team in Edinburgh built a better switch.
Start with enhancers. An enhancer is a short piece of DNA that proteins land on to turn a gene up. In nature they cluster into super-enhancers, and those clusters are what give a cell its identity. The team asked whether they could build one from scratch, tuned to glioblastoma.
They began with the two proteins that keep a glioblastoma stem cell in its stem state, SOX two and SOX nine. They chopped the places those proteins bind into short fragments, tested about four and a half thousand of them one at a time, kept the ones that fired only in tumor cells, and chained the winners together. The result is a synthetic super-enhancer. In tumor stem cells it is as strong as the strongest switch in common use. In normal cells it is almost silent.
Then they wired two payloads behind it.
The first is an enzyme borrowed from the cold-sore virus. On its own it does nothing. But it converts a harmless antiviral pill into a drug that poisons dividing cells, so the tumor makes the poison that kills it.
The second is interleukin twelve, an alarm that calls in the immune system. Sent through the bloodstream it is far too toxic. Made inside tumor cells, it stays where it is needed. And because both payloads ride one message, the alarm fades as the tumor cells die.
In mice with an aggressive glioblastoma, one injection cleared the tumor in twenty of twenty-four animals, and they stayed well eleven months. Given fresh tumor cells months later, ten of them grew no tumor at all. Only about a fifth of the tumor cells had to receive the gene. The immune system found the rest.
Mice are not people, and earlier attempts at this kind of therapy struggled in the clinic. That is what this trial is for. It is called ADePT. About sixty-eight adults with new or returning glioblastoma get one injection into the tumor, then the antiviral pill for up to three weeks, then their planned surgery. The first questions are safety and dose. It runs at the Royal Infirmary of Edinburgh with Faye Robertson, and at Ohio State with Bradley Elder.
Everything in this film comes from the published record, and it is not medical advice.
Sources behind this film
Most common cancer that starts in the adult brain; ~11,000 US cases a year; most in their sixties
Most common cancer that starts in the adult brain; ~11,000 US cases a year; most in their sixties; Payload one: enzyme from the cold-sore virus turns a harmless antiviral pill into a poison for dividing cells; Both payloads on one message, so the alarm fades as tumor cells die; ADePT; ~68 adults; new or returning glioblastoma; one injection, antiviral pill up to three weeks, then planned surgery; safety and dose first (+1 more lines)
Stupp R. N Engl J Med, 2005
Surgery, then radiation with a chemotherapy pill; half of patients lived under fifteen months
Koeber U. Nature, 2026
No edge; cells wander into healthy brain; a few behave like stem cells and rebuild the tumor; Existing on switches are too weak or too leaky; Enhancers; clusters called super-enhancers define cell identity; Built around SOX2 and SOX9 (+10 more lines)
ADePT; ~68 adults; new or returning glioblastoma; one injection, antiviral pill up to three weeks, then planned surgery; safety and dose first
The drug
TGX-007 administered as single intratumoural injection
Oral valaciclovir administered 3 times daily for 14 - 21 days
Patients will receive TGX-007 by a direct intratumoural injection and will then take the pro-drug valacyclovir orally for up to 21 days before proceeding to standard of care surgery. The study is split into two phases. Phase I will treat patients at different dose levels of TGX-007 to identify the Optimal Biological Dose that will be used to further expand the study into Phase II.
The study
The goal of this clinical trial is to first define the Safety and Optimal Biological Dose (OBD) of study drug TGX-007 and to then further investigate the safety and efficacy in patients with newly diagnosed or recurrent Glioblastoma. TGX-007 is a gene therapy drug delivered by a harmless adeno-associated virus (AAV) vector which delivers two combined therapeutic payloads to enable killing of proliferative cells and activation of an anti-tumour immune response.
One is herpes simplex virus thymidine kinase (HSV-tk), which converts the pro-drug valaciclovir into an active drug that can kill tumour cells and the other is interleukin 12 (IL-12), which activates the body's immune system to recognise and fight the tumour. Patients newly diagnosed with glioblastoma suitable for standard of care surgery and chemoradiotherapy or patients with recurrent glioblastoma suitable for further surgery may be eligible for the study.
Eligibility
Inclusion criteria as written on the registry, trimmed. The full list, with exclusions, is on the live record.
For you, or someone you love
A complex diagnosis brings new questions every week, in a trial and out of one. Triangle keeps your whole medical file together, reads it with you in plain language, and helps you and your family decide what to ask next.
Then $9 a month. Cancel anytime.
Requested from your hospitals and clinics through the national networks. Add scans, pathology and anything on paper.
Reports explained as they come in, with lab values you can follow before treatment, during a trial and after.
Ask about your own file, and walk in with questions for your oncologist or the trial team.
Share one profile with the family helping you, and with your doctors.
Members also get a deeper analysis of their records and any sequencing data, including clinical trials that may fit, reviewed by a licensed physician before they receive it.
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.
How these trials work: what Phase 1 actually is · common questions Not clinical evidence.